Johnson & Johnson
said on Wednesday that an early test showed positive results for its new drug-coated stents, designed to prevent reclogging of propped open arteries.
The 400-patient study, conducted by the Paris Course on Revascularization, found that only 2% of patients treated with the drug-coated stents, which are metal tubes designed to prop open collapsed arteries, suffered reclogging.
According to a press release, the findings represent a 94% reduction in restenosis, or reclogging of arteries propped open with stents, over the use of bare metal stents. The company said, "We are extremely impressed by the consistency in findings" between the current test and the large-scale study in Europe and Latin America.
Johnson & Johnson hopes to use the clinical data to gain marketing clearance in the U.S. for the drug-coated stents, which are already sold in Europe.
Shares of Johnson & Johnson were climbing about 2% to $61.75 on the news in premarket trading after closing at $60.64 Tuesday.